Can a Blood Test Detect Alzheimer’s Disease? What Quebec Families Should Know

A simple blood test could play an increasingly important role in evaluating Alzheimer’s disease.

New research reported in Quebec on September 14, 2026 suggests that measuring a combination of proteins in the blood may provide information not only about Alzheimer’s-related changes but potentially about how advanced those changes are.

Researchers from the University of Gothenburg and other international centres identified a combination of seven blood proteins that may improve the detection of more advanced brain changes associated with Alzheimer’s disease.

The research adds to rapid progress in Alzheimer’s blood tests and blood-based biomarkers, which could eventually make parts of the diagnostic process more accessible and less invasive.

But what can these blood tests actually tell us—and are they available to Quebec patients today?

Can a Blood Test Detect Alzheimer’s Disease?

Blood tests are increasingly being used to measure biological markers associated with Alzheimer’s disease.

Two of the best-known Alzheimer’s-related proteins are amyloid beta and tau. Abnormal changes involving these proteins are associated with Alzheimer’s disease and can be investigated using biomarkers.

Blood-based tests can measure biomarkers such as phosphorylated tau, including p-tau217, as well as certain amyloid-related measurements.

These tests have progressed rapidly. Some Alzheimer’s blood tests have already been cleared by the U.S. Food and Drug Administration for use in people experiencing cognitive symptoms.

However, an Alzheimer’s blood test is not the same as a routine screening blood test, and a blood result alone should not be interpreted as a complete Alzheimer’s diagnosis.

What’s New in the Latest Alzheimer’s Blood Test Research?

The research reported in September goes beyond simply asking whether Alzheimer’s-related biological changes may be present.

Researchers examined multiple proteins in the blood and identified a combination of seven proteins that may help distinguish more advanced Alzheimer’s-related brain changes.

This could eventually be important because Alzheimer’s disease develops along a continuum. Understanding the extent of disease-related changes may help clinicians and researchers better characterize an individual’s condition.

The findings are promising, but they should not be interpreted to mean that a new seven-protein Alzheimer’s test is now routinely available at clinics or laboratories across Quebec.

Further validation and clinical implementation are required before emerging research becomes standard patient care.

How Accurate Are Alzheimer’s Blood Tests?

Accuracy depends on the particular test, biomarker, patient population and way the test is used.

Research into blood biomarkers such as p-tau217 has produced encouraging results, and clinical guidance is evolving rapidly.

The Alzheimer’s Association published clinical practice guidance in 2025 on using blood-based biomarkers as part of the diagnostic evaluation of people with cognitive impairment in specialized care.

Importantly, the guidance emphasizes that blood biomarker testing should follow an appropriate clinical evaluation and that results must be interpreted in the context of the patient’s overall health and symptoms.

In other words:

Blood tests can provide valuable evidence, but they are one part of an Alzheimer’s assessment—not a replacement for the healthcare professional evaluating the patient.

Can an Alzheimer’s Blood Test Replace Other Diagnostic Tests?

Not necessarily.

Evaluating possible Alzheimer’s disease can involve several components, depending on the individual:

• medical and family history;
• discussion of memory or cognitive changes;
• cognitive assessments;
• physical and neurological evaluation;
• routine laboratory testing to investigate other possible causes;
• brain imaging;
• cerebrospinal fluid testing or specialized biomarker testing when appropriate.

Blood-based biomarkers may make parts of this process more accessible because collecting blood is generally simpler and less invasive than obtaining cerebrospinal fluid through a lumbar puncture.

But the appropriate diagnostic pathway depends on the patient and should be determined by qualified healthcare professionals.

Should People Without Symptoms Get an Alzheimer’s Blood Test?

Current guidance does not recommend Alzheimer’s biomarker testing as routine clinical screening for cognitively healthy people without symptoms.

This distinction is particularly important as public awareness of Alzheimer’s blood tests increases.

Someone should not order a biomarker test simply because they are concerned about developing Alzheimer’s later in life and then attempt to interpret the result independently.

Research is investigating whether blood biomarkers could identify Alzheimer’s-related changes years before symptoms develop. However, using such tests in symptom-free individuals raises important questions about interpretation, treatment and the psychological consequences of knowing the result.

For now, people concerned about memory loss, confusion or other cognitive changes should discuss those symptoms with an appropriate healthcare professional.

Why Could Blood-Based Testing Matter for Seniors?

Traditional Alzheimer’s assessments may require several appointments, specialist consultations or specialized diagnostic procedures.

That can be challenging for some older adults, particularly those with limited mobility.

Blood-based biomarkers could eventually make parts of Alzheimer’s evaluation more accessible by allowing useful biological information to be obtained from a blood sample.

This could be especially valuable as Quebec’s population ages and demand for dementia assessment and care continues to grow.

However, easier blood collection does not eliminate the need for professional clinical assessment.

What Does This Mean for Blood Tests at Home?

The growing role of blood-based diagnostics also highlights the value of making blood collection more accessible for seniors and people with reduced mobility.

A+ Solutions Home Health Care provides blood tests at home in Montreal and surrounding Greater Montreal communities, allowing patients to have eligible physician-ordered blood samples collected at home rather than travelling to a collection centre.

This can be helpful for seniors who:

• have difficulty walking or travelling;
• depend on family members for transportation;
• are recovering after hospitalization or surgery;
• require recurring laboratory testing;
• find clinic waiting rooms difficult or stressful.

The samples are then transported to the appropriate laboratory for analysis.

It is important to distinguish mobile blood collection from Alzheimer’s diagnosis.

A+ Solutions does not diagnose Alzheimer’s disease through a home blood test. Whether a specific Alzheimer’s biomarker test is available, appropriate and orderable in Quebec depends on the healthcare professional, laboratory and current clinical guidance.

How A+ Solutions Supports Seniors at Home

Blood collection is only one aspect of healthcare that can increasingly be delivered at home.

A+ Solutions Home Health Care supports seniors and families throughout Montreal, the West Island, Laval, Longueuil and surrounding Greater Montreal communities.

Depending on individual needs, services include:

• blood tests at home;
• private nursing;
• senior care and personal support;
• post-hospital and post-operative care;
• medication-related support;
• mobile foot care.

For older adults experiencing memory or cognitive difficulties, home healthcare can also reduce some of the logistical burden associated with routine healthcare.

However, concerns about memory loss, confusion or possible dementia should always be discussed with an appropriate physician or healthcare professional.

When Should Families Seek Medical Advice About Memory Changes?

Occasional forgetfulness does not automatically mean someone has Alzheimer’s disease.

However, families should consider discussing changes with a healthcare professional when memory or thinking difficulties begin interfering with everyday life.

Examples may include repeated difficulty remembering recent information, becoming confused in familiar situations, problems completing previously familiar tasks, or noticeable changes in judgment or behaviour.

These symptoms can have many possible causes, some of which may be treatable.

A professional assessment is therefore more appropriate than assuming the symptoms are Alzheimer’s disease or relying on a single laboratory test.

The Future of Alzheimer’s Diagnosis Is Changing

Blood-based biomarkers represent one of the most significant developments in Alzheimer’s diagnostics in recent years.

Research now suggests that blood testing may help clinicians identify Alzheimer’s-related biological changes with increasing accuracy and potentially provide additional information about disease progression.

But the technology needs to be understood in context.

An Alzheimer’s blood test does not replace a comprehensive medical assessment, and emerging research should not be confused with tests that are routinely available to every patient today.

For Quebec families, the most important development is that Alzheimer’s assessment may gradually become more accessible and less invasive as validated blood-based technologies move into clinical practice.

And as more healthcare testing becomes possible through blood samples, convenient home blood collection may become increasingly valuable for seniors and patients with limited mobility.

Frequently Asked Questions About Alzheimer’s Blood Tests

Can a blood test detect Alzheimer’s disease?

Blood tests can measure biomarkers associated with Alzheimer’s-related changes in the brain. Certain validated blood-based biomarker tests can support diagnosis in symptomatic patients, but results should be interpreted alongside a comprehensive clinical evaluation.

What biomarkers are used in Alzheimer’s blood tests?

Research and clinical tests may measure biomarkers associated with amyloid beta and tau proteins. One particularly important biomarker being studied and used in some tests is phosphorylated tau 217, or p-tau217.

Can I get an Alzheimer’s blood test in Quebec?

Availability depends on the specific test, laboratory, clinical indication and current Canadian and Quebec healthcare practices. Patients concerned about Alzheimer’s disease should first discuss their symptoms and appropriate testing with a physician or qualified healthcare professional.

Should healthy people get an Alzheimer’s blood test?

Current clinical guidance does not recommend routine Alzheimer’s biomarker testing for cognitively healthy, symptom-free individuals outside appropriate research settings. These tests are primarily being used to support evaluation of people with cognitive impairment.

Can A+ Solutions perform an Alzheimer’s blood test at home?

A+ Solutions provides mobile blood collection for eligible laboratory tests, but does not independently diagnose Alzheimer’s disease. Availability of a specific Alzheimer’s biomarker test depends on the laboratory, medical requisition and current clinical requirements.

What should I do if a family member is experiencing memory problems?

Speak with a physician or appropriate healthcare professional. Memory changes can have many possible causes, and a comprehensive assessment can help determine whether additional cognitive testing, laboratory tests, imaging or specialist evaluation is appropriate.